Introduction
============

In the article by Magnani et al, "Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States," which published online March 19, 2015, and appeared in the March 2015 issue of the journal (*J Am Heart Assoc*. 2015;4:e001505 doi: 10.1161/JAHA.114.001505), several corrections were needed.

In Figure 2, panel C was incorrect (duplicating panel B). The correct version of Figure 2 now appears in the article and is presented here.In Figure 5, on page 6, a single point estimate marker was omitted from Figure 5. The correct version of Figure 5 now appears in the article and is presented here.On page 6, left column, first paragraph, line 7, "(HR 1.22; 95% CI 0.92 to 1.62, *P*=0.16)" has been corrected to "(HR 1.24; 95% CI 0.92 to 1.66, *P*=0.16)."In Figure 6, on page 7, the total number of eGFR≥60 was presented as 17073 and has been corrected to 17037.In the legends to Figures 5 and 6, on pages 6 and 7, respectively, the following explanatory note has been added: "The prior stent subgroup is limited to those who underwent percutaneous revascularization."

The authors regret these errors.

The online version of the article has been updated and is available at <http://jaha.ahajournals.org/content/4/3/e001505>.
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![CV death, MI, or stroke in major subgroups. CI indicates confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HR, hazard ratio; MI, myocardial infarction. The prior stent subgroup is limited to those who underwent percutaneous revascularization.](jah3-4-e000633-g5){#fig05}
